TomoTherapy Marks Five Years of Clinical Success : Customer- and Survivor-Focused Events Highlight Monthlong Commemoration

Share Article

TomoTherapy Incorporated (NASDAQ: TOMO) recently commemorated the fifth anniversary of the first patient treatment on a clinical TomoTherapy® Hi·Art® system, which occurred July 1, 2003, at Thompson Cancer Survival Center in Knoxville, Tenn. The commemoration began in mid-June with the annual North America Hi·Art System Users Meeting and Symposium on Helical TomoTherapySM. It ended on July 12, 2008, with Radiate Hope, a fundraising event and celebration of cancer survivorship spearheaded by TomoTherapy employees, and sponsored by the company.

News Image
the best technical decision we've made.

"July 1, 2003 marked a new day in cancer care," said Fred Robertson, CEO of TomoTherapy. "Since that first treatment, we've installed more than 200 Hi·Art systems, and customers have delivered over one million CT-guided, intensity-modulated radiation therapy (IMRT) fractions via our platform. In looking back at five years of clinical acceptance and success, we wanted to honor the great work of customers, as well as the inspiring lives of those treated with our technology."

To commemorate this anniversary, TomoTherapy hosted the customer- and survivor-focused events in Madison, Wis., home to TomoTherapy headquarters and the University of Wisconsin, where the concepts of helical TomoTherapy were first explored and developed.

More than 100 TomoTherapy customers and guests attended the fifth annual North America Users Meeting and Symposium on Helical TomoTherapy on June 13 and 14, 2008. The two-day event focused on harnessing the power of the Hi·Art platform and highlighted its increased use for stereotactic procedures. Notable presentations included:

An Liu, Ph.D., assistant professor of medical physics, City of Hope National Medical Center, on optimizing efficiency of stereotactic radiosurgery delivery with helical TomoTherapy; Michael Bloom, R.T. (R)(T), radiation oncology manager, Memorial Hospital Cancer Center, on his center's use of TomoTherapy's stereotactic capabilities for the treatment of lung cancer; Tewfik Bichay, Ph.D., director of medical physics, Lacks Cancer Center, St. Mary's Health Care, on his center's extensive experience using the Hi·Art system for cranial radiosurgery; Mark Ritter, M.D., Ph.D., associate professor of radiation oncology, University of Wisconsin School of Medicine and Public Health, on a clinical trial to investigate use of the Hi·Art system for new approaches to hypofractionated radiation therapy for prostate cancer; Ke Sheng, Ph.D., assistant professor of medical physics, University of Virginia Health System, on accounting for target motion in stereotactic body radiotherapy for lung tumors; Craig Stevens, M.D., Ph.D., division chief of radiation oncology, H. Lee Moffitt Cancer Center & Research Institute, on why he considers Moffitt's decision to purchase three Hi·Art systems, "the best technical decision we've made." The second annual Radiate Hope event, held on July 12, 2008, raised more than $70,000 for cancer research and support organizations in the Madison, Wis. area. The event attracted approximately 400 attendees for a family-focused celebration of survivorship. Eight cancer survivors addressed the crowd, sharing the stories of their cancer journeys and discussing how TomoTherapy's treatment technology has impacted their lives.

About Radiate HopeSM

Radiate Hope began as a project of the employees of TomoTherapy Incorporated. The goal was to celebrate the impact of their work on the lives of cancer patients, and to raise funds for cancer awareness, education, research, and treatment assistance. Radiate Hope was incorporated in May 2007 as a non-profit and operates in accordance with Section 501(c)(3) of the Internal Revenue Code. Radiate Hope Foundation is supported entirely by donations and many volunteers throughout the Madison, Wis. community. To learn more, go to http://www.radiatehope.org.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2008 TomoTherapy Incorporated. All rights reserved. TomoTherapy, CTrue, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patty Kitowski
Visit website